民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构 | 民生证券股份有限公司 | 上市公司简称 | 博瑞医药 | | --- | --- | --- | --- | | 保荐代表人 | 黄丹青、邵航 | 上市公司代码 | 688166 | 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕1883 号）核准，并经上海证 券交易所同意，博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或 "公司"）向社会公众公开发行人民币普通股（A 股）股票 41,000,000 股，每股 发行价格为人民币 12.71 元，募集资金总额 521,110,000.00 元，扣除承销及保荐 费用、会计师费用、律师费用、信息披露费用及其他发行手续费共计人民币 81,125,361.23 元后，募集资金净额为人民币 439,984,638.77 元。上述募集资金已 于 2019 年 10 月 31 日全部到位，且经公证天业会计师事务所（特殊普通合伙） 审验并出具了苏公 W[2019]B079 号《验资报告》 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.45% on August 28, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Top Performers - Duorui Pharmaceutical (301075) saw a closing price of 44.40, with a rise of 7.87% and a trading volume of 59,400 shares, totaling a transaction value of 259 million [1] - Guangshengtang (300436) closed at 131.39, up 5.49%, with a trading volume of 172,000 shares and a transaction value of 2.192 billion [1] - Xingqi Eye Medicine (300573) closed at 68.70, increasing by 3.71%, with a trading volume of 318,800 shares and a transaction value of 2.239 billion [1] Underperformers - Nanjing New Pharmaceutical (681899) closed at 15.41, down 9.25%, with a trading volume of 455,800 shares and a transaction value of 701 million [2] - Meinuohua (603538) closed at 26.04, down 8.18%, with a trading volume of 387,900 shares and a transaction value of 1.017 billion [2] - Borui Pharmaceutical (688166) closed at 98.04, down 6.63%, with a trading volume of 225,300 shares and a transaction value of 2.201 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.702 billion from institutional investors, while retail investors contributed a net inflow of 3.086 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Huadong Pharmaceutical (000963) had a net inflow of 89.0375 million from institutional investors, while retail investors saw a net outflow of 84.9691 million [3] - Guangshengtang (300436) experienced a net inflow of 52.2637 million from institutional investors, with retail investors also seeing a net outflow of 25.6366 million [3] - Nanjing New Pharmaceutical (688189) had a net inflow of 17.9937 million from institutional investors, while retail investors faced a net outflow of 41.5515 million [3]

Group 1 - The A-share market's innovative drug concept stocks have experienced a collective decline for the third consecutive day, with notable drops including Nanjing New Pharmaceutical falling over 11% and Yuandong Bio down over 9% [2] - Other companies such as Borui Pharmaceutical, Zhaoyan New Drug, and Kangyuan Pharmaceutical also saw declines exceeding 6%, while Shutaishen, Hite Bio, Shouyao Holdings, and Wanbangde dropped over 5% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [3]

该公司属于化学制药板块，主营业务涵盖创新药研发与生产。作为江苏地区上市公司，博瑞医药在合成 生物、减肥药等领域具有业务布局。 博瑞医药8月27日报收105.00元，较前一交易日下跌4.50元，成交额达11.11亿元。当日股价波动区间为 105.00-112.40元，换手率为2.44%。 从资金流向来看，8月27日主力资金净流出9010.04万元，近五个交易日累计净流出2.91亿元。当前公司 总市值为443.91亿元，市盈率为856.32倍。 风险提示：股市有风险，投资需谨慎。（本内容由AI生成，仅供参考，不构成投资建议。） ...

Group 1 - The core viewpoint indicates that China's innovative pharmaceutical industry is potentially at a historic turning point, transitioning from "generic following" to "original innovation" [1] - The National Medical Products Administration reported that since the 14th Five-Year Plan, 204 innovative drugs and 265 innovative medical devices have been approved, with 50 innovative drugs and 49 innovative medical devices approved in the first seven months of this year [1] - The number of innovative drugs under research in China accounts for approximately 30% of the global total, highlighting the country's significant role in the global pharmaceutical landscape [1] Group 2 - The Sci-Tech Innovation Pharmaceutical ETF (588860) has shown active trading, with a turnover rate of 21.95% and a total transaction volume of 46.9145 million yuan as of August 26, 2025 [1] - The ETF has seen a substantial increase in shares, with a growth of 14 million shares in the past week, and has experienced continuous net inflows totaling 22.8123 million yuan over four days [1] - The management and custody fee rate for the Sci-Tech Innovation Pharmaceutical ETF is 0.52%, the lowest among similar ETFs tracking the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index [2]

8月26日，博瑞医药大宗交易成交4.4万股，成交额433.62万元，占当日总成交额的0.44%，成交价98.55元，较市场收盘价109.5元折价10%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 国联民生证券股份 | 国投证券股份有限 | | | 2025-08-26 | 博瑞医药 | 688166 | 98.55 | 216.81 | 2.2 | 有限公司深圳益田 | 公司江苏分公司 | | | | | | | | | 路证券营业部 | | | | | | | | | | 瑞银证券有限责任 | 国投证券股份有限 | | | 2025-08-26 | 博瑞医药 | 688166 | 98.55 | 216.81 | 2.2 | | | | | | | | | | | 公司上海花园石桥 | 公司江苏分公司 | | | | | | | | | 路证券营业部 | | | ...

Core Viewpoint - The news highlights the performance of the STAR Market and the launch of Huawei's new AI SSD, indicating a growing interest in AI storage solutions and the potential for investment opportunities in the tech sector [3][4]. Group 1: STAR Market Performance - As of August 26, 2025, the STAR Market 100 Index rose by 0.61%, with notable increases in constituent stocks such as Huafeng Technology (up 13.04%) and Zhuhai Guanyu (up 12.17%) [3]. - The STAR 100 Index ETF saw a 0.78% increase, marking its third consecutive rise, with a latest price of 1.3 yuan [3]. - Over the past week, the STAR 100 Index ETF accumulated a 5.49% increase, with a trading volume of 99.8865 million yuan and a turnover rate of 1.36% [3][4]. Group 2: Investment Trends and Fund Performance - The STAR 100 Index ETF experienced a net inflow of 27.3865 million yuan over the last ten trading days, despite a recent net outflow of 6.55234 million yuan [4]. - The ETF's net asset value increased by 23.84% over the past six months, ranking it 514 out of 3544 in the index stock fund category [5]. - The ETF's management fee is 0.15%, and its tracking error is 0.020%, indicating a competitive cost structure and high tracking precision compared to similar funds [5][6]. Group 3: Huawei's AI SSD Launch - Huawei is set to launch a new AI SSD on August 27, targeting the AI storage market by addressing the limitations of traditional HBM with innovative technology [3]. - The new product aims to meet the demands for large capacity and high performance in AI training and inference processes, potentially revitalizing the AI storage market [3]. - Huawei plans to collaborate with integrated machine manufacturers to enhance the current market landscape, suggesting a strategic move to increase competitiveness in the AI storage sector [3]. Group 4: Domestic Computing Power Chain - The release of DeepSeek-V3.1 is expected to boost the domestic computing power chain, with significant growth anticipated in related infrastructure due to increased capital expenditure from domestic internet companies [4]. - The focus on domestic computing power and its supporting industries, such as optical modules and switches, is projected to maintain high demand and growth in the coming years [4].

进一步统计，近3个月内该股累计发生19笔大宗交易，合计成交金额为2.32亿元。 证券时报·数据宝统计显示，博瑞医药今日收盘价为109.50元，上涨3.32%，日换手率为2.65%，成交额 为12.24亿元，全天主力资金净流入4656.59万元，近5日该股累计下跌2.06%，近5日资金合计净流出4.09 亿元。 两融数据显示，该股最新融资余额为22.96亿元，近5日减少2.21亿元，降幅为8.79%。（数据宝） 博瑞医药8月25日大宗交易平台出现一笔成交，成交量40.00万股，成交金额4380.00万元，大宗交易成交 价为109.50元。该笔交易的买方营业部为中信证券股份有限公司深圳滨海大道证券营业部，卖方营业部 为中国中金财富证券有限公司天津滨海新区证券营业部。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 8月25日博瑞医药大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | ...

进一步统计，近3个月内该股累计发生19笔大宗交易，合计成交金额为2.32亿元。该股近5个交易日累计 下跌2.06%，主力资金合计净流出4.09亿元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 8月25日，博瑞医药（维权）收涨3.32%，收盘价为109.50元，发生1笔大宗交易，合计成交量40万股， 成交金额4380万元。 第1笔成交价格为109.50元，成交40.00万股，成交金额4,380.00万元，溢价率为0.00%，买方营业部为中 信证券股份有限公司深圳滨海大道证券营业部，卖方营业部为中国中金财富证券有限公司天津滨海新区 证券营业部。 责任编辑：小浪快报 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-25 | 博瑞医药 | 688166 | 109.5 4380 | 40 | 中信证券股份有限 | 中国中金财富证券 | | | | | | | 公司深圳滨海大道 | 有限公司天津滨海 | | | | | | | 1 + = | 11 17 3 7 4 2 2 1 . 4 0 | 8月25日，博瑞医药大宗交易成交40万股，成交额4380万元，占当日总成交额的3.45%，成交价109.5元，较市场收盘价109.5元持平。 ...